DIABETES PREVENTION TRIAL-TYPE 1 DIABETES (DPT-1)

这项多中心随机试验旨在评估 小剂量胰岛素治疗联合周期性持续胰岛素治疗 注射胰岛素(“β细胞静息”)以延缓和/或预防 胰岛素依赖型糖尿病患者一级亲属的发病情况 患有IDDM的个人。非糖尿病，胰岛细胞抗体阳性 胰岛素分泌第一时相也有变化的个体 都有资格随机化。在前一年，大约 100个IDDM家庭参与了以前的研究 联系了糖尿病遗传学，并告知了DPT-1试验的情况。 对一些感兴趣的家庭成员进行了抗体筛查，但 未发现ICA+个体。招聘工作将继续在 即将到来的一年。

This multicenter randomized trial is designed to evaluate the ability of low dose insulin therapy, in association with periodic continuous insulin infusions ('beta cell rest') to delay and/or prevent the development of insulin dependent diabetes in first degree relatives of individuals with IDDM. Nondiabetic, islet cell antibody positive individuals who also have alterations in first phase insulin secretion are qualified for randomization. During the previous year, approximately 100 IDDM families who had participated in previous studies of the genetics of diabetes were contacted and informed about the DPT-1 trial. Antibody screening of some interested family members was performed but no ICA+ individuals were identified. Recruitment will continue in the coming year.